📰 ReutersReutersCodex · 实盘不做把握 8/10
北京时间·🕒 发布 07-30 17:15:16时区推断·⟳ 抓取 07-30 17:18:28·⚡ 决策 07-31 01:31:27 +8h12m·88.8 天前
GSK与未上市Relation Therapeutics达成最高1.1亿美元AI药物发现合作
Relation Therapeutics为未上市主体，无法直接交易；GSK只是支付合作方，最高1.1亿美元里程碑金额相对大型药企收入、研发预算和市值过小。
📄 原文Reuters↗ 原文
British biotech firm Relation Therapeutics said on Wednesday it had entered into a research collaboration with GSK (G…
不做 GSK（GSK.GB）
Relation未上市不可交易；GSK为超大药企，最高1.1亿美元早研合作对收入、市值和短期利润影响显著不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 medium · price-in 风险 medium ↗
关键理由
- Relation Therapeutics为未上市主体，无法直接交易；GSK只是支付合作方，最高1.1亿美元里程碑金额相对大型药企收入、研发预算和市值过小。
- 该合作属于早期AI药物发现数据与模型训练合作，不是已商业化药品、获批、销售放量或明确利润增量。
- AI药物发现主题外溢到其他上市公司缺少同向、可量化、短周期传导，不能仅凭行业验证做主题交易。
主要风险
- 若后续披露Relation上市计划、GSK取得明确临床资产权益或金额大幅上修，可由新信号重新评估。
原文全文
展开原文 · 848 字
British biotech firm Relation Therapeutics said on Wednesday it had entered into a research collaboration with GSK (GSK.L) worth up to $110 million to generate human cellular datasets and train AI models for identifying potential new drug targets.
Here are some details:
Under the agreement, Relation will generate large-scale datasets showing how human cells respond to genetic and drug interventions, with the information used to train AI foundation models, including Relation's MORGAN platform.
The collaboration builds on an earlier partnership between the companies focused on fibrotic diseases and osteoarthritis.
GSK has been increasing investment in research and development as it seeks to strengthen its drug pipeline, while also expanding the use of AI to improve the efficiency and success rate of drug discovery.
Here are some details:
Under the agreement, Relation will generate large-scale datasets showing how human cells respond to genetic and drug interventions, with the information used to train AI foundation models, including Relation's MORGAN platform.
The collaboration builds on an earlier partnership between the companies focused on fibrotic diseases and osteoarthritis.
GSK has been increasing investment in research and development as it seeks to strengthen its drug pipeline, while also expanding the use of AI to improve the efficiency and success rate of drug discovery.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。